This is where your breakthroughs break through.
The cancer-fighting cell
and gene therapy CDMO
The Ottawa Hospital’s Biotherapeutics Manufacturing Centre (BMC) — a not-for-profit, early-phase cell and gene therapy CDMO focused on turning promising advanced oncology and rare disease research into clinically proven therapies — is now Boreal Biomanufacturing.
A rich history of
manufacturing success.
Boreal is built on repeated success — on the production line, in patient rooms at The Ottawa Hospital, and out in the world.
This is where the hope that drives development of investigational products for cancer and rare disease is realized, through Phase I-III development and GMP-compliant production. It’s home to creative breakthroughs and disciplined manufacturing capabilities. And to a team of determined professionals working side-by-side with more than a thousand clinicians to give each patient something even better than hope: a tomorrow brighter than today.
Pioneered the development of oncolytic virotherapy treatments
Co-led development of the first made-in-Canada CAR-T therapy and public health infrastructure
Fostered the development and successful launch of multiple advanced therapy start-ups
Let’s work together
to make things better.
You’ve got a game-changing idea to treat cancer or rare disease. We’re ready to bring it to life. Let’s get started.
Get StartedPhase I-III Contract Development
& Manufacturing Experts.
Go from the seed of an idea to a fully realized product.
Boreal brings together translational expertise and deep early-phase capabilities — as well as direct access to patients through a leading clinical centre conducting hundreds of active trials — to offer true bench-to-bedside capabilities, and streamline your efforts to turn research into care.
Our manual and automated solutions for personalized cancer therapies deliver the product modality that works best for your innovation. We specialize in the development of investigational products, whether your program requires a single dose or thousands.
- Generation of material suitable for preclinical, toxicology studies and engineering batches
- Analytical/microbiological method development
- Upstream/downstream manufacturing process development
- Vectored products, autologous and allogenic cell products, and cell lines
- Master cell and virus banks
- GMP-compliant Production for Investigational Products
- In accordance with Health Canada GUI-0001 & GUI-0119 and U.S. Food and Drug Administration 21CFR210 and 21CFR211
- Testing of incoming raw materials for production
- Sampling and testing of GMP environmental and personnel monitoring
- GMP-compliant, product analytical testing
- Clinical Trial Application (CTA) preparation and lifecycle management
- Chemistry, Manufacturing and Controls (CMC) documentation
- Health Canada strategy and communication
- Pre- and post-submission support
Boreal by the numbers
Work with people who’ve put in the work.
The Boreal Difference.
The early-phase CDMO for oncology and rare disease.
As unique as a fingerprint.
Every project — just like every cancer, and every patient — is unique. Our processes evolve to ensure we give our clients’ therapies every chance to succeed. The focus is always on results, and relentlessly working our way toward the best, most efficient way to achieve them.
As interconnected as
the boreal forest.
You get the benefit of our deep roots: almost 20 years of insight, experience, and institutional knowledge. So you can count on getting expert guidance, making the right connections, and giving your advanced therapy the greatest chance to grow and thrive.
As dynamic as a
living promise.
We take the trust you put in us seriously. At every step, we evaluate, strategize, and enhance — establishing the conditions for success, supporting the transition from preclinical development to first-in-human studies, and helping programs progress through rigorous clinical development.
Learn More →Oncology and rare disease viral vector and cell therapy experts.
Implausible missions welcome.
Our clients think big, no matter what size organization they come from. They’re tackling some of the most complex challenges in medicine, and they need a partner with the expertise to help turn ambitious ideas into clinical-stage therapies.
Sound like you?
You’ll find a proven, fully engaged ally in Boreal.
We can help you advance complex therapies swiftly and strategically. We can take your inspired ideas and transform them into real-world breakthroughs. And we can do the most important thing of all: streamline the path from bench to bedside and speed the delivery of viable, clinically tested treatments.
Start Here →
GMP Facilities for viral
vector and cell and gene
therapy manufacturing.
Boreal already offers advanced therapy development, production, and quality control capabilities here in our Canadian facilities, including six CL2 GMP suites across multiple grades.
And they’re about to get even better. In 2029, we’ll double our current capacity with the opening of our new facility inside the University of Ottawa’s Advanced Medical Research Centre, bringing Boreal together with researchers, innovators, and biotechnology companies in a collaborative environment designed to accelerate therapeutic development.
Get Details →
